Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definition
1.2 Base estimates & calculations
1.3 Forecast parameters
1.4 Data collection
1.5 Data validation
1.6 Data sources
1.6.1 Primary
1.6.2 Secondary
1.6.2.1 Paid sources
1.6.2.2 Unpaid sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Rising prevalence of acute lymphoblastic leukemia
3.2.1.2 Increasing number of product approvals
3.2.2 Industry pitfalls & challenges
3.2.2.1 High treatment cost
3.2.2.2 Adverse effects associated with the treatment
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Porter's analysis
3.5.1 Supplier power
3.5.2 Buyer power
3.5.3 Threat of new entrants
3.5.4 Threat of substitutes
3.5.5 Industry rivalry
3.6 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company matrix analysis
4.3 Company market share analysis
4.4 Competitive positioning matrix
4.5 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Therapy, 2018 – 2032 ($ Mn)
5.1 Key trends
5.2 Chemotherapy
5.2.1 Hyper - CVAD regimen
5.2.2 CALGB 8811 regimen
5.2.3 Linker regimen
5.2.4 Nucleoside inhibitors
5.2.5 Oncaspar
5.3 Targeted therapy
5.4 Radiation therapy
5.5 Stem cell transplantation
5.6 Immunotherapy
Chapter 6 Market Estimates and Forecast, By Type, 2018 – 2032 ($ Mn)
6.1 Key trends
6.2 B-cell acute lymphoblastic leukemia
6.3 T-cell acute lymphoblastic leukemia
6.4 Philadelphia chromosome
Chapter 7 Market Estimates and Forecast, By Age Group, 2018 – 2032 ($ Mn)
7.1 Key trends
7.2 Children
7.3 Adults
Chapter 8 Market Estimates and Forecast, By Gender, 2018 – 2032 ($ Mn)
8.1 Key trends
8.2 Male
8.3 Female
Chapter 9 Market Estimates and Forecast, By Treatment Providers, 2018 – 2032 ($ Mn)
9.1 Hospitals & clinics
9.2 Cancer care centers
9.3 Research and academic institutes
Chapter 10 Market Estimates and Forecast, By Region, 2018 – 2032 ($ Mn)
10.1 Key trends
10.2 North America
10.2.1 U.S.
10.2.2 Canada
10.3 Europe
10.3.1 Germany
10.3.2 UK
10.3.3 France
10.3.4 Spain
10.3.5 Italy
10.3.6 Rest of Europe
10.4 Asia Pacific
10.4.1 China
10.4.2 Japan
10.4.3 India
10.4.4 Australia
10.4.5 Rest of Asia Pacific
10.5 Latin America
10.5.1 Brazil
10.5.2 Mexico
10.5.3 Rest of Latin America
10.6 Middle East and Africa
10.6.1 South Africa
10.6.2 Saudi Arabia
10.6.3 Rest of Middle East and Africa
Chapter 11 Company Profiles
11.1 Bristol Myer Squibb Company
11.2 Celegene Corporation
11.3 Eisai Co Ltd.
11.4 Erytech Pharma
11.5 F. Hoffmann-La Roche Ltd.
11.6 Genmab A/S
11.7 GlaxoSmithKline PLC
11.8 Novartis AG
11.9 Pfizer, Inc.
11.10 Sanofi S.A.
